Logicum | Scientia | Humanitas

Tyme Technologies, Inc.

Using a Unique Metabolic Approach to Treat Stage IV Metastatic Cancer.

Tyme Technologies, Inc. is a research and development company focused on creating medicines that utilizes the body’s immune system to treat diseases. We at Tyme believe that the body has the ability to fight off major diseases and heal itself. Tyme is researching a mechanism that it believes may work alongside the body’s immune system to fight Stage IV Metastatic Cancer.

Tyme hopes to provide a novel compound for physicians to use in a treatment regimen for patients fighting six major cancers (breast, lung, prostate, gastric, esophageal and pancreatic cancers) responsible for 62% of the annual cancer deaths in the United States. SM-88, Tyme’s proprietary drug candidate compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. SM-88 is designed to penetrate the living cancer cells and introduce multiple mechanisms to kill the cell. Inducing transfer of electrons in the cancer cells may allow catalyzed external free radicals to react and stress the cell. SM-88 is a combination of low dose agents used for non-cancer treatment.

Proprietary and Patented

Tyme’s Novel Approach: SM-88

SM-88 is Investigational and Undergoing Clinical Studies to Evaluate Safety and Effectiveness. It Has Not Been Approved by the FDA.

Tyme’s proprietary and patented SM-88 compound is a combination of unique chemistry and established drugs. SM-88 is designed to penetrate exclusively the living cancer cells and introduce multiple mechanisms to kill the cell without any toxicity or involvement of healthy body tissue. SM-88 may achieve cancer cell death by inducing transfer of electrons in the cancer cells that allow catalyzed external free radicals to react and stress the cell. The compound could create an engineered metabolic response which may result in the altering of the cancer’s cell defenses to oxidative stress. Tyme plans to study whether an SM-88 bolstered immune system can fight the disease to a stability and remission.

Mechanism of Action

SM-88 is Designed to Target Only Active Cancer Cells.

Chemotherapy compounds are toxic, and are designed to interfere with the mechanism of cell division but are not selective, and thus toxic to the organs and the body as a whole. Unlike traditional Chemotherapy, SM-88 is designed to target only active cancer cells and to force them to be vulnerable to the body’s natural defenses and processes.

Participating Institutions

Mayo Clinic
Mount Sinai
Albert Einstein College of Medicine
Emory Healthcare
MD Anderson Cancer Center
Medical College of Wisconsin
The University of Kansas